Phase 2 N=219 Trial for Patients With Newly Diagnosed Primary Central Nervous System (CNS) Lymphoma
Central Nervous System Lymphoma
Primary: Complete Remission Rate After Primary Chemotherapy — 23; 30; 49 Percentage of participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=6 Combination Chemotherapy, Monoclonal Antibody, and Radiation Therapy in Treating Patients With Primary Central Nervous System Lymphoma
Brain and Central Nervous System Tumors · Lymphoma
Primary: Number of Phase I Participants Experiencing Toxicity — 1; 3 Participants
N/A N=52 Combined Immunochemotherapy Followed By Reduced Dose Radiation Therapy (RT) for Patients With Newly Diagnosed Primary Central Nervous System Lymphoma
Lymphoma
Primary: Total Number of Participants Who Experienced Acute Treatment Related Adverse Events — 52 Participants
Phase 2 N=44 Rituximab and Combination Chemotherapy in Treating Patients With Newly Diagnosed Primary CNS Lymphoma
Lymphoma
Primary: Complete Response Rate After Remission Induction — 66 percentage of participants
Phase 2 N=40 High-dose Sequential Chemoimmunotherapy for B-cell Lymphomas With Central Nervous System Involvement
B-cell Lymphomas
Primary: Event-free Survival — 16 Participants
Phase 2 N=33 Rituximab, Methotrexate, Procarbazine and Vincristine Followed by High-dose Chemotherapy With Autologous Stem-cell Rescue in Newly-diagnosed Primary CNS Lymphoma
CNS Lymphoma · CNS Brain Cancer · Non-Hodgkin's Lymphoma
Primary: Number of Participants Evaluated for Toxicity — 33 Participants
Phase 2 N=30 High Dose Chemotherapy and Stem Cell Transplant for Non-Hodgkin's Lymphoma or Central Nervous System (CNS) Lymphoma
Non-Hodgkin's Lymphoma · CNS Lymphoma
Primary: Proportion of Patients With CNS Involvement by B-cell NHL, Relapsed PCNSL, or Relapsed PIOL Who Are Alive and Progression-free at One Year — 28 Participants
Phase 2 N=91 Rituximab, Methotrexate, Vincristine Sulfate, Procarbazine Hydrochloride, and Cytarabine With or Without Radiation Therapy in Treating Patients With Primary Central Nervous System Lymphoma
Chemotherapeutic Agent Toxicity · Cognitive/Functional Effects · Lymphoma
Primary: Progression-free Survival — 2.1; NA years — p=0.015
Phase 2 N=12 Chemotherapy and HAART to Treat AIDS-related Primary Brain Lymphoma
AIDS-Related-Primary Central Nervous System Lymphoma
Primary: Number of Patients Alive at 2 Years Without Recurrent Brain Lymphoma or Severe Neurocognitive Defects — 8 Participants
Phase 2 N=75 New Combination of Chemoimmunotherapy for Systemic B-cell Lymphoma With Central Nervous System Involvement
Diffuse Large B-cell Lymphoma
Primary: 1 Year Progression Free Survival (PFS) — 58 Percentage of participants
Phase 2 N=4 Buparlisib (BKM120) In Patients With Recurrent/Refractory Primary Central Nervous System Lymphoma (PCNSL) and Recurrent/Refractory Secondary Central Nervous System Lymphoma (SCNSL)
Lymphoma · Primary Central Nervous System Lymphoma · Recurrent/Refractory Secondary Central Nervous System Lymphoma
Primary: Progression Free Survival — 39 days
Phase 2 N=30 CPG 7909 + Local Radiotherapy in Recurrent Low-Grade Lymphomas
Non-Hodgkin Lymphoma · Mycosis Fungoides
Primary: Objective Response Rate (ORR) — 26.7; 35.7 percentage of treated subjects
Phase 2 N=66 A Study of Nivolumab in Relapsed/Refractory Primary Central Nervous System Lymphoma (PCNSL) and Relapsed/Refractory Primary Testicular Lymphoma (PTL)
Lymphoma
Primary: BICR-Assessed Objective Response Rate (ORR) — 6.4; 26.3 Percentage of participants
Phase 2 N=12 Pembrolizumab in Relapsed and Refractory Gray-Zone Lymphoma (GZL), Primary Central Nervous System Lymphoma (PCNSL), and Other Extranodal Diffuse Large B-cell Lymphomas
Non-Hodgkin Lymphoma · Lymphoma · Diffuse Large B-Cell Lymphoma
Primary: Best Overall Response Rate of Pembrolizumab in Participants With Relapsed/Refractory Gray-zone Lymphomas (GZL) and Extra-nodal Diffuse Large B-cell Lymphomas (DLBCL)…
N/A N=21 Molecular and Whole-body MR Imaging in Lymphomas
Lymphoma · Hodgkin Disease · Lymphoma, Non-Hodgkin
Primary: 68Ga-DOTANOC Uptake in Lymphomas With PET/CT — 3.1 Standardized Uptake Value
Phase 2 N=57 A Study for Patients With Non-Hodgkin's Lymphomas
T-Cell Lymphoma · B-Cell Lymphoma
Primary: Tumor Response Rate (RR) (Percentage of Participants Exhibiting Complete Response [CR] or Complete Response Unconfirmed [CRu] or Partial Response [PR]) — 0; 0; 0; 0…
Phase 3 N=24 Radiation Therapy Compared With Chemotherapy and Radiation Therapy in Treating Patients With Newly Diagnosed Primary Central Nervous System (CNS) Germ Cell Tumor
Brain Tumor · Central Nervous System Tumor
Primary: Event-free Survival — 1; 1; 0; 0 participants
Phase 2 N=17 LSA4 Protocol for the Treatment of Advanced Pediatric and Adolescent Non-Hodgkins Lymphoma
Non-Hodgkin's Lymphoma
Primary: Complete Remission — 10 participants
Phase 2 N=43 CAR T Cell Receptor Immunotherapy for Patients With B-cell Lymphoma
Primary Mediastinal B-cell Lymphoma · Diffuse, Large B-cell Lymphoma · Diffuse Large B-Cell Lymphoma Transformed From Follicular Lymphoma
Primary: Number of Participants With a Response Assessed by the Response Criteria for Malignant Lymphoma — 2; 3; 2; 3 Participants
Phase 2 N=25 Chemotherapy Combined With Radiation Therapy for Newly Diagnosed CNS AT/RT
Central Nervous System Tumor, Pediatric
Primary: 2-yr Overall Survival — 0.70 probability
Phase 2 N=78 Iodine I 131 Monoclonal Antibody 3F8 in Treating Patients With Central Nervous System Cancer or Leptomeningeal Cancer
Brain and Central Nervous System Tumors · Intraocular Melanoma · Lung Cancer
Primary: Six-month Overall Survival — 67; 11 Participants
Phase 2 N=73 Radiation Therapy Alone for the Treatment of Stage 1 and 2 Mucosa-Associated Lymphoid Tissue (MALT) Lymphoma
Ann Arbor Stage I Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue · Ann Arbor Stage II Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue · Extranodal Marginal Zone Lymphoma
Primary: Relapse-free Survival (RFS) — 83 months
Phase 2 N=54 Safety and Feasibility Study of Combination of State of Art Chemoimmunotherapy, Intensive Central Nervous System Prophylaxis and Scrotal Irradiation to Treat Primary Diffuse Large B-cell Lymphoma of Testis
Large B-cell Diffuse Lymphoma of Testis
Primary: Adverse Events Assessment — 6; 3; 3 Participants
Phase 2 N=72 CT-011 MAb in DLBCL Patients Following ASCT
Lymphoma, Large Cell, Diffuse · Lymphoma, Mixed Cell, Diffuse · Primary Mediastinal Large B-Cell Lymphoma
Primary: Progression-free Survival — 72 Percent
Phase 2 N=46 S0313 Cyclophosphamide, Doxorubicin, Vincristine, Prednisone, and Radiation Therapy Followed By Rituximab and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Stage I or Stage II Non-Hodgkin's Lymphoma
Lymphoma
Primary: Progression-free Survival — 89 percentage of participants
Phase 2 N=31 Antineoplaston Therapy in Treating Patients With Low-Grade Non-Hodgkin's Lymphoma
Low-Grade Lymphoma
Primary: Number of Participants With Objective Response — 1; 2; 14; 6 Participants
Phase 2 N=30 A Phase 2 Intratumoral Injection PF-3512676 Plus Local Radiation in Low-Grade B-Cell Lymphomas
Lymphoma, Non-Hodgkin · Lymphoma · Lymphomas: Non-Hodgkin Follicular / Indolent B-Cell
Primary: Overall ObjectiveResponse (ORR) Rate — 0; 7; 19; 4 participants
N/A N=15 Radiosurgery and Avastin for Recurrent Malignant Gliomas
Malignant Glioma
Primary: Central Nervous System (CNS) Toxicity — 1 participants
Phase 2 N=36 Lenalidomide, Rituximab, Cyclophosphamide, and Dexamethasone in Treating Patients With Previously Untreated Low-Grade Non-Hodgkin Lymphoma
Lymphoma
Primary: Assessment of Tumor Response — 30.3; 54.5 percentage of participants
Phase 3 N=356 Radiation Therapy in Preventing Central Nervous System (CNS) Metastases in Patients With Non-Small Cell Lung Cancer
Lung Cancer
Primary: Overall Survival — 28.5; 25.3 months — p=0.2853